Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

25
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
25
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

380
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

561
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
561
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

34
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension.

Alimentary pharmacology & therapeutics·2026
Same author

A Review of Therapies for Primary Biliary Cholangitis.

Gastroenterology & hepatology·2026
Same author

The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease.

Nature communications·2026
Same author

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial.

Hepatology (Baltimore, Md.)·2026
Same author

New therapies for primary biliary cholangitis.

Hepatology international·2026
Same author

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.

Hepatobiliary surgery and nutrition·2026

Related Experiment Video

Updated: Apr 28, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K

Predicting outcome in primary biliary cirrhosis.

Willem J Lammers1, Kris V Kowdley2, Henk R van Buuren1

  • 1Dept. of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Annals of Hepatology
|June 14, 2014
PubMed
Summary

Predicting outcomes in primary biliary cirrhosis (PBC) involves identifying risk factors like male gender and high bilirubin. Ursodeoxycholic acid (UDCA) therapy and liver transplantation improve prognosis for this autoimmune liver disease.

More Related Videos

Determining Bile Duct Density in the Mouse Liver
07:35

Determining Bile Duct Density in the Mouse Liver

Published on: April 30, 2019

6.5K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.3K

Related Experiment Videos

Last Updated: Apr 28, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K
Determining Bile Duct Density in the Mouse Liver
07:35

Determining Bile Duct Density in the Mouse Liver

Published on: April 30, 2019

6.5K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.3K

Area of Science:

  • Hepatology
  • Autoimmune Diseases
  • Liver Transplantation

Background:

  • Primary biliary cirrhosis (PBC) is a chronic autoimmune liver condition.
  • It can lead to liver failure and premature death if untreated.
  • Accurate outcome prediction is crucial for patient management and treatment timing.

Purpose of the Study:

  • To identify factors associated with progressive primary biliary cirrhosis.
  • To evaluate the impact of ursodeoxycholic acid (UDCA) and liver transplantation on PBC outcomes.
  • To assess tools for predicting prognosis and complications like esophageal varices and hepatocellular carcinoma (HCC).

Main Methods:

  • Review of clinical and histological factors associated with disease progression.
  • Analysis of prognostic significance of symptoms, laboratory values, and complications.
  • Evaluation of the effectiveness of UDCA therapy and liver transplantation.
  • Assessment of established risk scores (Mayo risk score, Newcastle Varices in PBC Score).

Main Results:

  • Younger age, male gender, cirrhosis, high bilirubin, low albumin, high alkaline phosphatase, esophageal varices, and HCC are linked to worse outcomes.
  • Lack of biochemical response to UDCA therapy is associated with progressive disease and increased HCC risk.
  • UDCA therapy and liver transplantation significantly improve patient outcomes.

Conclusions:

  • Several clinical, biochemical, and histological factors predict poor prognosis in primary biliary cirrhosis.
  • Male gender, cirrhosis, and non-response to UDCA are specific risk factors for HCC development.
  • UDCA therapy and liver transplantation offer significant benefits, and risk scores aid in prognosis and management.